Logo image of SILO

SILO PHARMA INC (SILO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SILO - US82711P2011 - Common Stock

0.3795 USD
-0.01 (-1.4%)
Last: 12/19/2025, 8:16:04 PM
0.3869 USD
+0.01 (+1.95%)
After Hours: 12/19/2025, 8:16:04 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SILO. SILO was compared to 531 industry peers in the Biotechnology industry. While SILO has a great health rating, there are worries on its profitability. SILO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SILO had negative earnings in the past year.
In the past year SILO has reported a negative cash flow from operations.
SILO had negative earnings in 4 of the past 5 years.
In the past 5 years SILO always reported negative operating cash flow.
SILO Yearly Net Income VS EBIT VS OCF VS FCFSILO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M

1.2 Ratios

With a Return On Assets value of -79.51%, SILO is not doing good in the industry: 67.11% of the companies in the same industry are doing better.
SILO has a Return On Equity (-101.36%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -79.51%
ROE -101.36%
ROIC N/A
ROA(3y)-46.88%
ROA(5y)-66.86%
ROE(3y)-61.66%
ROE(5y)-80.07%
ROIC(3y)N/A
ROIC(5y)N/A
SILO Yearly ROA, ROE, ROICSILO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

SILO's Gross Margin of 65.42% is amongst the best of the industry. SILO outperforms 80.15% of its industry peers.
In the last couple of years the Gross Margin of SILO has grown nicely.
SILO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.76%
GM growth 5Y29.76%
SILO Yearly Profit, Operating, Gross MarginsSILO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K

More info and screens

7

2. Health

2.1 Basic Checks

SILO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SILO has more shares outstanding
Compared to 5 years ago, SILO has more shares outstanding
SILO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SILO Yearly Shares OutstandingSILO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
SILO Yearly Total Debt VS Total AssetsSILO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

SILO has an Altman-Z score of -3.55. This is a bad value and indicates that SILO is not financially healthy and even has some risk of bankruptcy.
SILO has a Altman-Z score (-3.55) which is in line with its industry peers.
SILO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.55
ROIC/WACCN/A
WACC8.8%
SILO Yearly LT Debt VS Equity VS FCFSILO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

A Current Ratio of 8.70 indicates that SILO has no problem at all paying its short term obligations.
SILO has a better Current ratio (8.70) than 76.75% of its industry peers.
SILO has a Quick Ratio of 8.70. This indicates that SILO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.70, SILO is in the better half of the industry, outperforming 76.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.7
Quick Ratio 8.7
SILO Yearly Current Assets VS Current LiabilitesSILO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.56% over the past year.
SILO shows a decrease in Revenue. In the last year, the revenue decreased by 0.00%.
The Revenue has been growing by 12.51% on average over the past years. This is quite good.
EPS 1Y (TTM)21.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.88%
Revenue 1Y (TTM)0%
Revenue growth 3Y0.99%
Revenue growth 5Y12.51%
Sales Q2Q%0%

3.2 Future

SILO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.62% yearly.
SILO is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by 0.00% yearly.
EPS Next Y-25%
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%
EPS Next 5Y-21.62%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y0%
Revenue Next 5Y0%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SILO Yearly Revenue VS EstimatesSILO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
SILO Yearly EPS VS EstimatesSILO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 2 3 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SILO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SILO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SILO Price Earnings VS Forward Price EarningsSILO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SILO Per share dataSILO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

SILO's earnings are expected to decrease with -25.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%

More info and screens

0

5. Dividend

5.1 Amount

SILO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SILO PHARMA INC

NASDAQ:SILO (12/19/2025, 8:16:04 PM)

After market: 0.3869 +0.01 (+1.95%)

0.3795

-0.01 (-1.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10
Earnings (Next)03-26 2026-03-26/amc
Inst Owners11.65%
Inst Owner Change281.26%
Ins Owners1.63%
Ins Owner Change6.45%
Market Cap5.05M
Revenue(TTM)72.00K
Net Income(TTM)-5.08M
Analysts82.86
Price TargetN/A
Short Float %4.83%
Short Ratio1.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 70.21
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-0.93
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0.01
BVpS0.38
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.51%
ROE -101.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.42%
FCFM N/A
ROA(3y)-46.88%
ROA(5y)-66.86%
ROE(3y)-61.66%
ROE(5y)-80.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.76%
GM growth 5Y29.76%
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.7
Quick Ratio 8.7
Altman-Z -3.55
F-Score4
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.88%
EPS Next Y-25%
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%
EPS Next 5Y-21.62%
Revenue 1Y (TTM)0%
Revenue growth 3Y0.99%
Revenue growth 5Y12.51%
Sales Q2Q%0%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y0%
Revenue Next 5Y0%
EBIT growth 1Y-30.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-52.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.95%
OCF growth 3YN/A
OCF growth 5YN/A

SILO PHARMA INC / SILO FAQ

What is the fundamental rating for SILO stock?

ChartMill assigns a fundamental rating of 3 / 10 to SILO.


Can you provide the valuation status for SILO PHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to SILO PHARMA INC (SILO). This can be considered as Overvalued.


Can you provide the profitability details for SILO PHARMA INC?

SILO PHARMA INC (SILO) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for SILO stock?

The Earnings per Share (EPS) of SILO PHARMA INC (SILO) is expected to decline by -25% in the next year.